Please review management of difficult-to-regulate diabetic cats.
Q: Please review management of difficult-to-regulate diabetic cats.
A: Dr. Anthony C.G. Abrams-Ogg gave an excellent lecture on Difficult-to-Regulate Diabetic Cats at the 2008 American College of Veterinary Internal Medicine (ACVIM) Forum in San Antonio. Here are some relevant points:
The goal in treating diabetic cats is to regulate blood glucose levels. What constitutes poor regulation depends on what is considered acceptable regulation. For this discussion, difficult regulation in a cat is defined as failure to consistently control hyperglycemia, using a normal dose of an oral hypoglycemic agent (OHA) or insulin, for a sufficient part of the day to minimize PU/PD, normalize appetite, promote weight gain and activity, and lower fructosamine ± glycosylated hemoglobin levels.
While clinical signs and fructo-samine levels are frequently sufficient to confirm good regulation or to document poor regulation, blood-glucose curves may be required to identify the cause of poor regulation. Difficulty in obtaining reliable blood-glucose curves is one reason diabetic cats have been difficult to regulate. Continuous glucose monitoring systems may help in this regard.
Difficult regulation occurs in different forms:
1) Consistently bad days with persistent hyperglycemia
2) Inconsistent regulation, where the cat has good and bad days (the extreme is "brittle" diabetes with recurrent fluctuations between hyperglycemia/ketoacidosis and hypoglycemia)
3) Insulin resistance (IR), where unusually high doses of insulin are required to achieve regulation.
The diagnostic approach to the poorly regulated cat should be systematic and the potential causes critically reviewed for each case, but the specific approach will vary with the individual case depending upon the extent of initial evaluation for concurrent diseases, clinical signs, current therapy and owner desires. In some cases knowing that concurrent/underlying diseases have been ruled out by exhaustive screening will facilitate patience with adjustments in therapy. In other cases, where there are no obvious signs of a concurrent disorder, an owner may wish to try adjustments in therapy prior to extensive diagnostic testing. Ideally only one change in management should be made at a time.
Causes of difficult regulation include:
1) Problems with dietary therapy
2) Problems with OHA therapy
3) Problems with insulin therapy
4) Disorders causing insulin resistance.
More than one of these may be occurring in an individual case.
The diet is the most important medical therapy for diabetes mellitus in cats. There is mounting evidence that reducing carbohydrate and increasing protein content of the diet will improve regulation (and increase the likelihood of resolution of diabetes), and early dietary change is recommended for cats with persistent hyperglycemia without another obvious cause. It is not known if dietary change will always improve inconsistent regulation and reduce insulin requirements when there is therapeutic insulin resistance, but it is a rational maneuver. Grain-free or raw-meat diets should be considered for regulating diabetes mellitus in cats.
Feeding schedule is important in humans and in dogs, primarily because of post-prandial hyperglycemia (PPH), and changing feeding schedule has improved regulation in some dogs. This does not appear to be an important cause of poor regulation in cats. Cats tend to eat frequently and acute PPH does not appear to be an important event, especially if the diet's carbohydrate content is reduced. The occasional cat with polyphagia that consumes its food in one sitting may have acute PPH, which may be confirmed with a blood-glucose curve. Dividing the daily food into more frequent feedings (an automated feeder may help) is one solution.
The cat may not be getting its medication consistently, either because it is difficult to pill or is not eating the medication in its food. This should be reviewed, and the cat may be hospitalized for treatment and effect confirmed with blood-glucose measurements.
Oral hypoglycemic agents (OHAs) may be ineffective. Glipizide is used most often, with most cats responding within three months. Failure to respond after that time suggests there is insufficient functional beta-cell mass, and cats failing therapy are usually treated with insulin.
There are anecdotal reports of response to other OHAs, but, as with glipizide, failure of response in most cases is probably due to ineffectiveness of the drug.
Acarbose and dietary management has resulted in regulation, and acarbose have been anecdotally effective in improving regulation in cats receiving other treatments, but it is unlikely to be effective on its own, especially given the nature of PPH in cats. If there is a specific cause of IR, the role of continuing OHA therapy without initiating insulin while addressing the underlying disorder has not been defined.
Absorption is the crucial factor in determining insulin potency and duration of action, which together determine insulin effect. Variability in absorption is an important cause of inconsistent response in humans and is due to injection technique, patient characteristics and properties of the insulin. Under the most controlled experimental conditions, the intra-individual variability in insulin pharmaco-kinetics in humans is 20 percent, and >50 percent in clinical conditions. The situation likely is similar in cats.
Potential handling errors include use of outdated insulin, inactivation by exposure to excessive heat or light, violent shaking of the insulin bottle, insufficient mixing of the insulin preparation, drawing up an incorrect dose and dilution errors.
In humans, depth of injection, anatomic site and delay before needle withdrawal affect absorption, but temperature of the insulin and speed of injection do not.
Injection factors in cats anecdotally associated with poor regulation include unsuccessful injection, rubbing the injection site after injection, and interscapular vs. lateral thorax or flank injection. Variable injection technique is more likely to result in inconsistent regulation than in persistent hyperglycemia. Owner technique should be reviewed and consistency of injection emphasized.
If an insulin administration error is suspected, the cat may be hospitalized to ensure consistent injection and blood-glucose-lowering effect.Injection problems may be solved in some cases by changing to injection pens or needle-free injection.
The duration of insulin effect is not sufficiently long to achieve adequate BG control, which has been considered to be important in cats. A transient effect may be due to rapid absorption and/or to a counter regulatory phenomenon. A transient effect can be definitively diagnosed and distinguished from the Somogyi effect only by a blood-glucose curve.
The treatment is either to change to a longer-acting preparation or to give insulin twice a day. Increasing the dose will increase the duration of insulin effect, but carries an unacceptable risk for hypoglycemia. When changing from a shorter to longer-acting insulin preparation, the dose may be increased by 10 percent to 25percent to account for the reduced potency of the longer-acting preparation, but this is difficult with the small doses used in cats.
When changing from once to twice daily insulin injections, the dose should be reduced by about 25 percent to account for potential overlap in insulin effect. Cats are best regulated with twice-daily insulin, so this should be discussed with owners at the onset of treatment.
Absorption of insulin is normally incomplete, and is more so in cats than in dogs or humans. Zinc and protamine-based, longer-acting preparations are less completely absorbed than shorter-acting ones.
Absorption may be sufficiently incomplete that normoglycemia is not achieved with standard doses. This was primarily a problem with ultralente. In other cases, absorption is delayed such that a good part of the day is required before glucose falls. A blood-glucose curve demonstrates late-onset reduction in glucose or no effect.
The recommended treatment is to change insulin from PZI to NPH or pork lente, or, paradoxically, to glargine (different mechanism of absorption). Increasing the dose is not recommended because this increases the risk of late-onset hypoglycemia.
The insulin effect is sufficiently long so that an overlap occurs, resulting in a Somogyi effect. This is most likely to occur with twice-daily injection of a long-acting preparation. Treatment options include changing to once-daily injection of the existing preparation or to twice-daily injection of a shorter-acting preparation.
The peak insulin effect does not result in an adequate blood-glucose nadir or sufficient reduction in glucose for the duration of insulin action. Blood-glucose curve measurements every two hours usually are diagnostically adequate. The insulin dose should be increased by 0.25 to 0.5 U, unless previous dose adjustments have demonstrated that larger increments are required. Usually a minimum of seven days should be allowed for equilibration to the new dose before re-evaluation.
Too high a dose of insulin results in hypoglycemia, followed by rebound hyperglycemia due to counter regulatory hormone secretion. In one series, hypoglycemia developed within four to eight hours of insulin injection and rebound hyperglycemia (>17 mmol/L [300 mg/dl]) within three to six hours of the hypoglycemic nadir.
Signs of hypoglycemia may be seen — most likely lethargy, weakness and glazed expression. Somogyi effects may result in either persistent hyperglycemia or inconsistent regulation. The latter occurs because the counter regulatory hormones have a hyperglycemic effect for one to three days after the over-swing. During this period the excessive insulin dose results in good glycemic control. When the counter regulatory effect is over, the insulin dose causes hypoglycemia. A Somogyi effect recurs, and the cycle begins again.
Diagnosis requires a blood-glucose curve. Hourly measurements are recommended during the period of the anticipated blood-glucose nadir. It may be necessary to obtain consecutive BG curves in order to catch the day in which the over-swing occurs. Because this is labor-intensive and expensive, another approach is to reduce the dose of insulin and observe response.
Insulin absorption is normally inconsistent to a certain extent. If this variation is excessive it will result in inconsistent regulation. This is most likely to occur with a long-acting preparation. Daily blood-glucose curves will confirm inconsistent regulation, but it is difficult to prove that inconsistent absorption is the cause because insulin sensitivity may also vary daily. The most practical approach is to change insulin preparation and observe response.
The term "insulin resistance (IR)" is used in different ways. It refers to peripheral IR, which is reduced sensitivity of fat and muscle to insulin due to receptor and post-receptor defects. This is often a pathophysiologic event in Type 2 diabetes and is present in most diabetic cats.
Or, IR refers to therapeutic IR, where high doses of insulin are needed to regulate a diabetic patient. Therapeutic IR may be suspected when a dose >1.5 units/kg per injection is having a minimum effect on hyperglycemia, or when a cat is well-regulated but requires >2 units/kg per injection. This definition is imprecise and does not take into account potency of the insulin preparation.
Some cats with no apparent concurrent disease require higher doses of insulin to be well-regulated, presumably due to incomplete absorption. One approach in this case is to continue therapy unchanged and not perform a potentially fruitless diagnostic search. Disadvantage of this approach is the opportunity may be missed to reverse diabetes if it is secondary. If there are increasing insulin requirements, a concurrent/underlying disorder should definitely be pursued.
Anti-insulin antibodies formed in humans treated with animal-source insulin, especially with the less pure older preparations. Antibodies may bind insulin in the subcutaneous depot or in circulation, and, depending upon affinity, may have no effect, may result in inconsistent response, or may cause insulin resistance.
Antibody formation in cats is probably of minimal significance. Nonetheless, if a cat is poorly regulated and it appears to be an insulin-related problem, then a change in insulin is required, which could be a change in insulin species of origin.
Concurrent diseases cause IR by variably causing receptor defects, post-receptor defects and secretion of counter-pregulatory hormones. This may result in either persistent or fluctuating IR and cause-and-effect with the diabetes may not be clear. If a concurrent disease is identified, it should be noted that it may not be the (sole) cause of difficult regulation; curative treatment may not be possible or well-defined; or successful treatment may not resolve receptor or post-receptor defects.
Diabetes increases the risk for bacterial or fungal infection, which in turn causes IR.
A common site of infection is the urinary tract. Urinalysis may not be diagnostic, so urine culture should be performed early in the investigation. Many diabetic cats will have concurrent periodontal disease. Dentistry should be considered and the effect on regulation noted.
If a cause of IR has not been identified during work-up, a therapeutic trial with antibiotics may be considered to treat sub-clinical infection.
Diabetic cats may have chronic pancreatitis or exocrine pancreatic neoplasia. Pancreatic lipase immunoreactivity and ultrasound examination are currently the best non-invasive tests for pancreatitis.
Unfortunately, treatment of chronic pancreatitis is not well-defined, but prednisolone has been recommended. It is not known if excision of pancreatic tumors will improve regulation — in one study concurrent pancreatic neoplasia had no effect on survival.
Diabetic cats may also have hepatic lipidosis and cholangiohepatitis. Ultrasound study may identify hepatic abnormalities; definitive diagnosis is by liver biopsy. Concurrent liver diseases should be treated using standard recommendations. Nutritional support is important to facilitate insulin therapy by minimizing the risk for hypoglycemia. Pancreatitis, hepatic lipidosis and cholangiohepatitis may be risk factors for ketoacidosis.
Inflammatory and infectious disorders unrelated to diabetes may occur. The former include asthma and inflammatory bowel disease, which should be confirmed by standard work-up. Poorly regulated cats at risk should be tested for feline leukemia virus and feline immunodeficiency virus.
Sub-clinical cardiomyopathy is an uncommon cause of poor regulation. Echocardiography may be considered if other causes of poor regulation have been ruled-out and/or there are signs of heart disease.
Diabetes may result in hypertension, which is a cause of cardiac hypertrophy. However, hypertension is usually mild, and if heart disease is diagnosed it is probably primary.
Other concurrent diseases are those common to mature and geriatric cats. Hyperthyroidism and chronic renal disease are most common; neoplasia may also occur.
Hyperthyroidism causes insulin resistance, but secondary diabetes is rare and the need for very high doses of insulin is uncommon. Treatment of hyperthyroidism does, however, reduce insulin doses and improves consistency of regulation. Fructosamine levels are lowered in hyperthyroid cats and this should be taken into account when using this value to assess regulation.
Dr. Hoskins is owner of Docu-Tech Services. He is a diplomate of the American College of Veterinary Internal Medicine with specialities in small animal pediatrics. He can be reached at (225) 955-3252, fax: (214) 242-2200 or e-mail: jdhoskins@mindspring.com